SS
ITRM

SBI Securities’s Iterum Therapeutics ITRM Stock Holding History

SBI Securities’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16
Closed -$5 – 4094
2025
Q4 		$5 Hold
16
– – ﹤0.01% 3930
2025
Q3 		$11 Hold
16
– – ﹤0.01% 4022
2025
Q2 		$16 Sell
16
-2
-11% -$2 ﹤0.01% 3947
2025
Q1 		$22 Buy
18
+4
+29% +$6 ﹤0.01% 3832
2024
Q4 		$25 Buy
+14
New +$22 ﹤0.01% 3782

Other funds holding ITRM

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
GWP
Gen-Wealth Partners Zeeland, Michigan $360M AUM 27.44% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $12.4B AUM 62.79% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SBI Securities's ITRM Position: Q1 2026 in Review

SBI Securities sold out of Iterum Therapeutics (ITRM) in Q1 2026, closing a stake of 16 shares — an estimated $5 sold.

SBI Securities first reported a position in ITRM in Q4 2024 and held it in 5 quarters. The position peaked at $25 in Q4 2024. 18 funds tracked by Wall St. Rank hold ITRM as of Q1 2026.

  • SBI Securities reported no remaining Iterum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SBI Securities sold 16 Iterum Therapeutics shares in Q1 2026, an estimated $5.
  • SBI Securities first reported a position in Iterum Therapeutics in Q4 2024 and held it in 5 quarters.
  • SBI Securities's Iterum Therapeutics position peaked at $25 in Q4 2024.
  • 18 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.